参考文献(上下滑动查看) [1] United Nations Environment Programme. Mercury in products and wastes. 2008. http://www./hazardoussubstances/Portals/9/Mercury/AwarenessPack/English/UNEP-Mod1-UK-Web.pdf (Accessed on May 21, 2015). [2] Magos L. Review on the toxicity of ethylmercury, including its presence as a preservative in biological and pharmaceutical products. J Appl Toxicol 2001; 21:1. [3] Clarkson TW. The three modern faces of mercury. Environ Health Perspect 2002; 110 Suppl 1:11. [4] Fowler BA, Zalups RK. Mercury. In: Handbook on the Toxicology of Metals, Fifth ed, Nordberg GF, Costa M (Eds), Academic Press, 2022. p.539. [5] Sue Y. Mercury. In: Goldfrank's Toxicologic Emergencies, 10th ed, Hoffman RS, Howland M, Lewin NA, et al (Eds), McGraw-Hill, New York 2015.WHO. Inorganic mercury. Environmental Health Criteria 118. World Health Organization, Geneva, 1991. [6] 苏涛, 刘晓玲, 张宜苗, 等. 汞中毒相关肾小球疾病的临床病理分析 [J]. 中华肾脏病杂志,2011,27(5)333-336. [7] 王艳艳, 谌贻璞, 王国勤, 等. 七例化妆品汞中毒相关肾小球微小病变病报告 [J]. 中华肾脏病杂志 2013,11( 29) :804-806. [8] Mariani LH, Eddy S, AlAkwaa FM, et al. Precision nephrology identified tumor necrosis factor activation variability in minimal change disease and focal segmental glomerulosclerosis. Kidney Int. 2023 Mar;103(3):565-579. [9] Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med. 2023 Dec 28;389(26):2436-2445. [10] Egbuna O, Zimmerman B, Manos G, et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. N Engl J Med. 2023 Mar 16;388(11):969-979. [11] Caza TN, Storey AJ, Hassen SI, et al. Discovery of seven novel putative antigens in membranous nephropathy and membranous lupus nephritis identified by mass spectrometry. Kidney Int. 2023 Mar;103(3):593-606. [12] Xu Y, Huang Y, Zhang C, et al. Efficacy and safety of rituximab for primary nephrotic syndrome with acute kidney injury: A two-center prospective cohort study. Clin Immunol. 2023 Jan;246:109211. |
|
来自: 浪迹天涯soyxqc > 《文件夹1》